Bicara Therapeutics Inc. (BCAX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Bicara Therapeutics reported revenue of $0. Net income was -$137.9M, or -$2.52 per diluted share. Operating activities generated -$106.8M of cash, leaving -$107.1M of free cash flow. At fiscal year end, Bicara Therapeutics held $431.0M in total assets against $29.5M in total liabilities, including $96.7M of cash and equivalents.
Open the full interactive Bicara Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Bicara Therapeutics Key Stats
| Share Price | $17.34 |
|---|---|
| Market Cap | $1.18B |
| 52-Week Range | $13.93 – $30.40 |
| Shares Outstanding | 67.9 million (basic, 2026 Q2) |
Bicara Therapeutics Income Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Income | -$82.4M | -$155.6M |
| Pre-Tax Income | -$67.8M | -$137.7M |
| Income Tax | $180,000 | $217,000 |
| Net Income | -$68.0M | -$137.9M |
| Diluted EPS | -$4.05 | -$2.52 |
Bicara Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$36.3M | -$37.4M | -$56.2M | -$55.4M |
| Diluted EPS | -$0.67 | -$0.68 | -$0.93 | -$0.82 |
Bicara Therapeutics Balance Sheet
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash & Equivalents | $489.7M | $96.7M |
| Current Assets | $502.5M | $422.1M |
| Total Assets | $510.0M | $431.0M |
| Current Liabilities | $18.0M | $28.9M |
| Total Liabilities | $18.1M | $29.5M |
| Shareholders' Equity | $491.9M | $401.5M |
Bicara Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | |
|---|---|---|
| Cash From Operations | -$74.8M | -$106.8M |
| Cash From Investing | -$9,000 | -$318.5M |
| Cash From Financing | $334.0M | $32.3M |
| Free Cash Flow | -$74.8M | -$107.1M |
Figures from Bicara Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Bicara Therapeutics financials page for every line item.
Bicara Therapeutics Company Profile
| Ticker | BCAX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002023658 |
Frequently Asked Questions
What was Bicara Therapeutics' revenue in fiscal 2025?
Bicara Therapeutics (BCAX) reported revenue of $0 for fiscal 2025.
What was Bicara Therapeutics' net income in fiscal 2025?
Bicara Therapeutics reported net income of -$137.9M for fiscal 2025.
What was Bicara Therapeutics' earnings per share (EPS) in fiscal 2025?
Bicara Therapeutics' diluted EPS was -$2.52 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Bicara Therapeutics generate in fiscal 2025?
Bicara Therapeutics generated -$107.1M of free cash flow in fiscal 2025.
What was Bicara Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Bicara Therapeutics reported revenue of $0.
How many shares of Bicara Therapeutics are outstanding?
Bicara Therapeutics reported a weighted average of 67.9 million basic shares outstanding in 2026 Q2.
What is Bicara Therapeutics' market cap?
Based on its latest closing price, Bicara Therapeutics (BCAX) has a market capitalization of about $1.18B.
When does Bicara Therapeutics' fiscal year end?
Bicara Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Bicara Therapeutics headquartered?
Bicara Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.